Company Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -9.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -9.87% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -4.92% |
| 6 Months: | -2.68% |
| 3 Months: | +17.89% |
| 1 Month: | -15.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.68 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -9.9% CAGR over 5 years.
- Trading 44.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANIX Anixa Biosciences, Inc. PHARMA | 2.90 | -9.67 | $98.67M | 0.00% | -82.91% | -71.97% | -9.87% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2013 | Jul 2013 | Jan 2014 | Apr 2014 | Jul 2014 | Jan 2015 | Apr 2015 | Jul 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 513.00K | - | - | - | - | - | - | 210.00K | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.85M | -2.22M | -1.96M | -1.36M | -159.58K | 3.86M | -2.13M | -1.49M | -1.47M | -1.15M | -974.88K | -1.39M | -1.21M | -1.73M | -1.87M | -1.40M | -5.61M | -4.98M | -2.59M | -2.18M | -2.63M | -2.67M | -2.44M | -2.23M | -2.44M | -4.39M | -3.88M | -3.59M | -2.80M | -2.56M | -2.56M | -2.84M | -3.61M | -3.47M | -3.59M | -3.39M | -3.00M | -2.44M | -2.72M | -2.65M |
| Net Income | -2.48M | -2.58M | -3.61M | -3.25M | 411.00K | 3.75M | -2.24M | -1.60M | -1.59M | -1.27M | -1.10M | -3.60M | 160.49K | -1.79M | -1.84M | -1.38M | -5.48M | - | - | -2.14M | -2.59M | -2.64M | -2.56M | -2.21M | -2.40M | -4.33M | -3.83M | -3.54M | -2.75M | -2.32M | -2.29M | -2.51M | -3.25M | -3.14M | -3.28M | -3.18M | -2.79M | -2.26M | -2.56M | -2.52M |
| Diluted EPS | - | - | -0.02 | - | 0.04 | 0.41 | - | -0.18 | -0.18 | -0.15 | - | - | 0.02 | - | - | -0.08 | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | 0.08 | -0.07 | -0.08 | -0.10 | -0.10 | -0.10 | -0.10 | -0.09 | -0.07 | -0.08 | -0.07 |
| R&D Expense | - | - | - | - | - | - | - | - | 458.05K | 392.59K | 292.06K | 451.63K | 431.12K | 362.97K | 777.87K | 660.19K | 2.94M | 2.25M | 1.27M | 1.09M | 1.49M | 1.23M | 1.25M | 828.00K | 1.02M | 2.17M | 1.84M | 1.74M | 1.45M | 1.07M | 998.00K | 1.09M | 1.35M | 1.65M | 1.93M | 1.55M | 1.32M | 1.05M | 1.10M | 1.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 730.67K | 1.00M | 947.09K | 388.85K | 3.67M | 9.26M | 300.00K | 362.50K | 1.11M | 250.00K | - | 512.00K | - | 210.00K | 210.00K | - |
| Operating Income | -5.25M | -5.03M | -4.13M | -7.92M | -5.04M | -944.76K | -4.51M | -6.08M | -14.29M | -11.89M | -9.98M | -13.14M | -13.88M | -11.01M | -13.83M | -11.70M |
| Net Income | -5.18M | -7.38M | -4.25M | -10.08M | -9.61M | -1.38M | -5.02M | -5.01M | -14.00M | -11.65M | -10.02M | -12.95M | -13.60M | -9.81M | -12.55M | -10.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | 0.45 | -0.32 | -0.39 | -0.34 |
| R&D Expense | 3.01M | 3.12M | 2.21M | - | - | 711.39K | 1.56M | 1.60M | 6.81M | 5.47M | 4.38M | 6.19M | 6.70M | 4.77M | 6.40M | 5.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Dec 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.05M | 8.65M | 5.66M | 5.44M | 9.06M | 9.34M | - | 5.63M | 8.81M | 6.45M | 6.29M | 9.45M | 36.26M | 30.41M | 25.52M | 21.59M | 16.08M |
| Total Equity | 4.45M | 4.60M | 1.06M | -1.19M | -3.32M | 4.01M | 5.05M | - | 987.48K | 7.92M | 5.43M | 5.24M | 8.76M | 35.44M | 29.05M | 24.34M | 20.00M | 15.16M |
| Cash & Equivalents | 1.45M | 1.09M | 774.04K | 339.69K | 898.17K | 3.36M | 4.37M | - | 2.49M | 3.34M | 3.06M | 3.49M | 6.42M | 29.13M | 12.36M | 915.00K | 1.27M | 1.24M |
| Long Term Debt | - | - | - | - | - | - | 370.18K | 370.18K | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | 8.76M | 5.05M | 4.28M | - | 4.64M | 889.49K | - | - | 1.19M | 1.49M | 2.21M | 2.15M | 2.70M | 2.13M |
| Current Liabilities | - | 450.12K | 2.11M | 1.82M | 3.21M | 1.81M | 593.78K | - | 468.76K | 889.49K | 1.27M | 1.48M | 1.19M | 1.27M | 2.04M | 2.03M | 2.50M | 1.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.41M | -716.00K | -3.14M | -3.19M | -2.38M | 1.36M | -3.38M | -3.80M | -4.27M | -4.74M | -6.18M | - | -6.49M | -6.21M | -7.33M | -7.17M |
| Investing Cash Flow | 799.69K | -2.14M | 1.75M | 499.32K | -2.51M | 45.22K | 1.50M | -2.74M | 1.46M | -525.46K | -305.79K | - | -10.73M | -5.60M | 4.28M | 4.87M |
| Financing Cash Flow | 1.25M | 2.53M | 958.45K | 3.25M | 7.35M | -400.62K | -2.68K | 7.38M | 2.53M | 5.70M | 9.41M | - | 452.00K | 366.00K | 3.42M | 2.28M |
| Capital Expenditure | -2.07K | -9.03K | -1.60K | - | -6.68K | -54.78K | -146.52K | -30.19K | -38.40K | -175.46K | -15.79K | - | - | - | - | - |
| Free Cash Flow | -2.41M | -725.03K | -3.14M | - | -2.39M | 1.31M | -3.53M | -3.83M | -4.31M | -4.92M | -6.19M | - | -6.49M | -6.21M | -7.33M | -7.17M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -16.77M | -11.45M | 356.00K | -27.00K |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00K | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -718.3% | -501.2% | -436.6% | -2,036.2% | -137.5% | -10.2% | -1,503.0% | -1,676.0% | -1,284.4% | -4,756.0% | - | -2,565.6% | - | -5,243.3% | -6,586.2% | - |
| Net Margin % | -708.3% | -735.5% | -449.0% | -2,592.3% | -261.9% | -14.9% | -1,672.1% | -1,381.8% | -1,258.1% | -4,658.8% | - | -2,530.1% | - | -4,671.9% | -5,978.1% | - |
| ROE % | -112.6% | -697.3% | 356.2% | 303.6% | -239.6% | -27.3% | -508.0% | -63.2% | -257.5% | -222.5% | -114.3% | -36.6% | -46.8% | -40.3% | -62.8% | -72.1% |
| ROCE % | -54.7% | -76.9% | -107.7% | -355.4% | -69.6% | -10.8% | -87.4% | -76.7% | -275.7% | -247.1% | -120.7% | -37.5% | -48.9% | -46.9% | -72.4% | -82.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.83% | 1.33M | $3.68M |
| 2 | UBS Group AG | 1.68% | 585.43K | $1.62M |
| 3 | Laird Norton Wetherby Trust Company, LLC | 1.66% | 578.73K | $1.60M |
| 4 | D.A. Davidson & Co. | 1.55% | 539.27K | $1.49M |
| 5 | Geode Capital Management, LLC | 1.03% | 359.19K | $994.97K |
| 6 | Marshall Wace LLP | 0.94% | 328.33K | $909.48K |
| 7 | Blackrock Inc. | 0.57% | 199.75K | $553.32K |
| 8 | Vanguard Fiduciary Trust Co | 0.55% | 192.36K | $532.83K |
| 9 | State Street Corporation | 0.46% | 159.04K | $440.54K |
| 10 | GSA Capital Partners LLP | 0.34% | 117.47K | $325.38K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANIX
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & L…
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare C…
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investm…
Anixa Biosciences secures Korean patent for breast cancer vaccine
The patent expands Anixa’s IP portfolio beyond the US and existing international markets.
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number …
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York …
ANIX — Frequently Asked Questions
What is the current share price of Anixa Biosciences, Inc. (ANIX)?
As of 2026-09-19 21:16 PDT, Anixa Biosciences, Inc. (ANIX) trades at $2.90 on NasdaqCM. Its 52-week range is $2.35 to $5.22.
What is the market capitalisation of ANIX?
Anixa Biosciences, Inc. (ANIX) has a market capitalisation of $98.67M on NasdaqCM.
What is the P/E ratio of ANIX?
ANIX trades at a trailing price-to-earnings (P/E) ratio of -9.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.63.
What is the return on equity (ROE) of ANIX?
ANIX has a return on equity (ROE) of -71.97%. Its return on capital employed (ROCE) is -82.91%.
Is ANIX a good stock to buy?
This page provides a data-driven analysis of Anixa Biosciences, Inc. (ANIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.